Molecular Subtype Dictates Survival Outcomes in Encapsulated Papillary Carcinoma of the Breast: A Propensity Score-Matched SEER Analysis Supporting Treatment De-escalation
Clinical Breast Cancer · 2026
DOI: 10.1016/j.clbc.2026.02.012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Breast Cancer, 2026. Verfasst von Hongbo Li und 1 weiteren Autor:innen. Beteiligte Einrichtung: Breast and Thyroid Surgery, Jinhua People's Hospital, Jinhua, Zhejiang, China. Hauptthemen laut MEDLINE: Carcinoma, Papillary, Breast Neoplasms, Carcinoma, Ductal, Breast. Die Arbeit nennt 32 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Encapsulated papillary carcinoma (EPC) is a rare breast malignancy. Controversy persists over its classification and whether its prognosis stems from histology or biology. This study clarified the role of molecular subtypes in EPC prognosis and evaluated treatment de-escalation feasibility. PATIENTS AND METHODS: EPC and contemporary invasive ductal carcinoma (IDC) patients (2010-2019) were identified from the surveillance, epidemiology, and end results (SEER) database. A 1:1 propensity score matching (PSM) balanced baseline characteristics, including age, grade, stage, and molecular subtype. Breast cancer-specific survival (BCSS) and overall survival (OS) were analyzed using Kaplan-Meier and Cox regression. RESULTS: We included 165 EPC and 247,581 IDC patients. EPC patients were significantly older with lower grade tumors, less nodal involvement, and higher HR+/HER2- proportions (89.7% vs. 71.1%, P < .001). Before matching, EPC showed superior BCSS (P = .044). After PSM (n = 165 per group), no significant differences were observed in BCSS (P = .207) or OS (P = .733) between groups. Subgroup analysis of HR+/HER2- patients yielded consistent results. Chemotherapy usage was low (10.3%) in EPC with excellent outcomes; radiotherapy was an independent protective factor for survival. CONCLUSION: EPC's favorable prognosis is primarily driven by its molecular profile (HR+/HER2-) rather than histology. After subtype adjustment, EPC survival is equivalent to IDC. Findings support chemotherapy omission for most EPC patients while emphasizing radiotherapy for local control.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Breast and Thyroid Surgery, Jinhua People's Hospital, Jinhua, Zhejiang, China.
- Breast Surgery, Beihua University Affiliated Hospital, Jilin, Jilin, China. Electronic address: 2166715675@qq.com.
Zitieren
APA
Li, H., & Wang, Z. (2026). Molecular Subtype Dictates Survival Outcomes in Encapsulated Papillary Carcinoma of the Breast: A Propensity Score-Matched SEER Analysis Supporting Treatment De-escalation. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2026.02.012
Vancouver
Li H, Wang Z. Molecular Subtype Dictates Survival Outcomes in Encapsulated Papillary Carcinoma of the Breast: A Propensity Score-Matched SEER Analysis Supporting Treatment De-escalation. Clinical Breast Cancer. 2026. doi:10.1016/j.clbc.2026.02.012
BibTeX
@article{Li2026,
author = {Li, Hongbo and Wang, Zhiyong},
title = {Molecular Subtype Dictates Survival Outcomes in Encapsulated Papillary Carcinoma of the Breast: A Propensity Score-Matched SEER Analysis Supporting Treatment De-escalation},
journal = {Clinical Breast Cancer},
year = {2026},
doi = {10.1016/j.clbc.2026.02.012}
}
EUVIMED